BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

791 related articles for article (PubMed ID: 7503821)

  • 21. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.
    Fitzgerald DA; Hilton J; Jepson B; Smith L
    Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New pharmacological approaches: rhDNase].
    Tournier G; Sardet A; Grosskopf C; Baculard A; Delaisi B
    Rev Pneumol Clin; 1995; 51(3):193-200. PubMed ID: 7569583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease.
    Cimmino M; Nardone M; Cavaliere M; Plantulli A; Sepe A; Esposito V; Mazzarella G; Raia V
    Arch Otolaryngol Head Neck Surg; 2005 Dec; 131(12):1097-101. PubMed ID: 16365224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical trials of recombinant human DNase in cystic fibrosis patients.
    Aitken ML
    Monaldi Arch Chest Dis; 1993 Dec; 48(6):653-6. PubMed ID: 8124306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dornase alfa: a new option in the management of cystic fibrosis.
    Witt DM; Anderson L
    Pharmacotherapy; 1996; 16(1):40-8. PubMed ID: 8700791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis.
    Suri R; Marshall LJ; Wallis C; Metcalfe C; Bush A; Shute JK
    Am J Respir Crit Care Med; 2002 Aug; 166(3):352-5. PubMed ID: 12153969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
    Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
    Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
    Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
    Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?
    van der Giessen LJ; Gosselink R; Hop WC; Tiddens HA
    Eur Respir J; 2007 Oct; 30(4):763-8. PubMed ID: 17596273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
    McCoy K; Hamilton S; Johnson C
    Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. The Pulmozyme rhDNase Study Group.
    Fiel SB; Fuchs HJ; Johnson C; Gonda I; Clark AR
    Chest; 1995 Jul; 108(1):153-6. PubMed ID: 7606951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of rhDNAse in severely ill, non-intubated adult asthmatics refractory to bronchodilators: a pilot study.
    Silverman RA; Foley F; Dalipi R; Kline M; Lesser M
    Respir Med; 2012 Aug; 106(8):1096-102. PubMed ID: 22580235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of lobar atelectasis with bronchoscopically administered recombinant human deoxyribonuclease in cystic fibrosis?
    McLaughlin AM; McGrath E; Barry R; Egan JJ; Gallagher CG
    Clin Respir J; 2008 Apr; 2(2):123-6. PubMed ID: 20298317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical studies of rhDNase in moderately and severely affected patients with cystic fibrosis--an overview.
    Hodson ME
    Respiration; 1995; 62 Suppl 1():29-32. PubMed ID: 7792438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New treatment strategies in cystic fibrosis: rhDNase.
    Shah PL; Hodson ME
    Monaldi Arch Chest Dis; 1996 Apr; 51(2):125-9. PubMed ID: 8680379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability.
    Wills PJ; Wodehouse T; Corkery K; Mallon K; Wilson R; Cole PJ
    Am J Respir Crit Care Med; 1996 Aug; 154(2 Pt 1):413-7. PubMed ID: 8756815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis.
    Robinson M; Hemming AL; Moriarty C; Eberl S; Bye PT
    Pediatr Pulmonol; 2000 Jul; 30(1):16-24. PubMed ID: 10862158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNase in stable cystic fibrosis infants: a pilot study.
    Berge MT; Wiel Ev; Tiddens HA; Merkus PJ; Hop WC; de Jongste JC
    J Cyst Fibros; 2003 Dec; 2(4):183-8. PubMed ID: 15463871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of high-dose ibuprofen in patients with cystic fibrosis.
    Konstan MW; Byard PJ; Hoppel CL; Davis PB
    N Engl J Med; 1995 Mar; 332(13):848-54. PubMed ID: 7503838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.